Live Feeds
● LIVE Updated 2h ago · 12 sources tracked

GLP-1 lawsuit: Patient’s attorney describes life-changing effects from taking drug

Hundreds of people are suing makers of GLP-1 drugs, such as Ozempic and Wegovy, alleging the medications caused vision loss. Plaintiffs describe life-changing effects, including permanent blindness. Lawsuits claim drug manufacturers failed to warn users of the risk. Experts say claims will be hard to prove. The legal landscape is evolving, with multiple multidistrict litigations underway.

🎙️

Listen to Live Briefing

Real-time synthesized voice briefing · Live Feeds Desk

⏱ ~2 min
Speed:
RSS Source map (12)
⚡ Key Developments & Real-Time Context
Text size:
  • ✓ At least 12 cases of permanent blindness have been reported in users of GLP-1 drugs.
  • ✓ Hundreds of people are suing GLP-1 drugmakers over vision loss claims.
  • ✓ The MDL 3094 has 4022 cases, and MDL 3163 has 216 cases.
  • ✓ A Georgia nurse practitioner claims she woke up with vision loss in one eye after taking a GLP-1 drug.
🛡️ Source Corroboration: 12 independent reporting domains (90% confidence) ⏱ Read time: ~2 min

What changed

A recent hearing was held in the MDL 3163 vision-loss case, and the number of lawsuits in MDL 3094 and 3163 has increased.

Live updates

  1. GLP-1 lawsuits mount over vision loss claims

    Hundreds of people are suing makers of GLP-1 drugs, such as Ozempic and Wegovy, alleging the medications caused vision loss. Plaintiffs describe life-changing effects, including permanent blindness. Lawsuits claim drug manufacturers failed to warn users of the risk. Experts say claims will be hard to prove. The legal landscape is evolving, with multiple multidistrict litigations underway.

    Why it matters

    GLP-1 receptor agonists are popular weight-loss and diabetes medications. Recent reports of vision loss linked to these drugs have led to a surge in lawsuits. Regulatory bodies are investigating the rare eye risk. The outcome of these cases could impact the pharmaceutical industry and public perception of GLP-1 drugs.

    What is confirmed

    • At least 12 cases of permanent blindness have been reported in users of GLP-1 drugs.
    • Hundreds of people are suing GLP-1 drugmakers over vision loss claims.
    • The MDL 3094 has 4022 cases, and MDL 3163 has 216 cases.
    • A Georgia nurse practitioner claims she woke up with vision loss in one eye after taking a GLP-1 drug.
    • A patient's attorney describes life-changing effects from taking a GLP-1 drug, including permanent blindness.

    Still unconfirmed

    • Expert says GLP-1 vision loss claims will be hard to prove.

    What to watch next

    • The outcome of the MDL 3163 vision-loss case hearing
    • Any regulatory updates on GLP-1 drug safety
    • The number of lawsuits filed in MDL 3094 and 3163
    Sources used for this update (15)
    1. USA Today — Are GLP-1s causing blindness? What we know about rare cases
    2. ABC News - Breaking News, Latest News and Videos — What GLP-1 users should know about the potential risk of a rare type of vision loss
    3. The Boston Globe — Could GLP-1s be linked to a rare type of vision loss? Here’s what to know.
    4. Fox News — Popular weight-loss drugs face numerous lawsuits over rare ‘eye stroke’ linked to vision loss
    5. NewsNation — GLP-1 lawsuit: Patient’s attorney describes life-changing effects from taking drug
    6. MassLive.com — GLP-1 companies face flurry of lawsuits after consumers say drugs caused vision loss
    7. voz.us — 12 cases of permanent blindness: Internal medicine doctor explains risks behind popular GLP-1 drugs on 'Voz News'
    8. NewsNation — ‘Dark, scary’: GLP-1 user who lost vision says he received no warning
    9. KOAT — Expert says GLP-1 vision loss claims will be 'hard to prove'
    10. www.yahoo.com — Hundreds Sue GLP-1 Drugmakers Over Vision Loss as Regulators Weigh Rare Eye Risk
    11. www.yahoo.com — GLP-1 lawsuit: Patient’s attorney describes life-changing effects from taking drug
    12. www.yahoo.com — Novo’s next-gen weight-loss drug outperforms Zepbound in new trial
    confidence 90%
📊

Community Sentiment: How do you assess this situation?

Voice your perspective · Real-time aggregated sentiment from the Live Feeds community